期刊文献+

阿托伐他汀对原发性高血压患者血压及内-中膜厚度的影响 被引量:5

Effect of atorvastatins on BP and IMT
下载PDF
导出
摘要 目的探讨阿托伐他汀对原发性高血压(essential hypertension,EH)患者血压、血脂及内-中膜厚度(intima-media thick-ness,IMT)的影响。方法1、2级原发性高血压(EH)78例,分为正常胆固醇组(NC)和高胆固醇组(HC)组,各39例。NC组和HC组再按随机数字表分别分为他汀治疗组(NCS,HCS)和对照组(NCC,HCC),他汀治疗组每天予氨氯地平5 mg+阿托伐他汀20 mg;对照组每天予氨氯地平5 mg,均为12周。20例正常健康者为正常对照组。患者于基线及治疗12周后检测血压、血脂及IMT。结果EH各组患者经12周治疗后血压较前明显降低(P<0.05),以他汀治疗组下降幅度更加明显(P<0.05);NCC、HCC组血脂改变不明显(P>0.05),NCS和HCS组,TC、TG、LDL-C下降明显,HDL-C明显增高(P<0.05);EH组内血压、IMT、IMT/D及颈动脉斑块明显高于健康对照组(P<0.05);治疗后IMT及IMT/D均下降(P<0.05),治疗后各亚组内他汀治疗组与对照组比较下降有统计学意义(P<0.05);治疗后颈动脉斑块较对照组斑块改善不明显(P>0.05),但治疗组中位数较对照组有下降趋势。结论阿托伐他汀与氨氯地平等降压药物合用使降压效果更明显,有辅助降压作用;有效调脂的同时,可以使IMT/D改善明显,但短期内颈动脉斑块未见明显改善。 Aim To discuss the effect of atorvastatins on blood pressure and intima-media thickness(IMT) in patients with essential hypertension. Methods 78 patients with hypertension were selected,whose systolic blood pressure(SBP) was between 140 mmHg and 179 mmHg and diastolic blood pressure(DBP) was between 90 mmHg and 109 mmHg. The 39 EH patients with hypercholesterolemia(HC) and the rest without were randomized, double-blind, and assigned to atorvastatin ( 20 mg ·d^-1, NC group, n = 19, HC group, n=20 ) and amlodipine (5 mg·d^-1)or to the control group with amlodipine (5 mg·d^-1 ) (no lipid-lower-drugs NC group, n = 20, HC group, n = 19 ) for 12 weeks. 20 healthy people were selected as health control. Changes in blood pressure, blood cholesterol, and carotid arterial IMT were investigated respectively. Results Blood pressures decreased more markedly in patients taking statins no matter with or without hypercholesterolemia than in those not taking statins( P 〈 0.05 ). Compared with control group, there was a significant reduction in serum TC, TG and low density lipoprotein cholesterol concentrations in 20 mg atorvastatin group ( P 〈 0.05 ) and high density lipoprotein cholesterol concentrations was higher. The level of BP, IMT/D and carotid arterial plaque in EH group was higher than that in health control group. After treatment of atorvastatin, IMT and IMT/D decreased markedly( P 〈 0.05 ), but carotid arterial plaque didn't develop obviously. Through the analysis of the results, we could see the tendency of improvement (P 〉 0.05 ). Conclusion Atorvastatin together with amlodipine can significantly lower blood pressure better. Modulating blood lipid effectively, it can develop IMT in short time, but not in carotid arterial plaque.
出处 《安徽医药》 CAS 2010年第3期331-334,共4页 Anhui Medical and Pharmaceutical Journal
关键词 阿托伐他汀 原发性高血压 内-中膜厚度 atorvastatins essential hypertension IMT
  • 相关文献

参考文献13

  • 1McInnes GT, Cicero FG, Dormi A, et al. Lowering blood pressure for cardiovascular riskreduction [J]. J Hypertens Suppl,2005,23 ( 1 ) : S3 - 8.
  • 2Kannel WB. Risk stratification in hypertension : new insights from the Framingham study[ J]. Am J Hypertens,2000,1:3S - 10S.
  • 3Ferdinand KC, Kleinpeter MA. Management of hypertension and dyslipidemia [ J ]. Curr Hypertens Rep,2006,8 (6) :489 - 96.
  • 4Prandin MG, Cicro AF, Donni A, et al. Prospective evaluation of the effect of statins on blood pressure control in hypertensive patients in clinical practise [ J ]. Nutr Metab Cardiovasc Dis ( 2009 ) , doi : 10.1016/j, numecd,2009,05. 010.
  • 5Farmer JA, Gotto AM Jr. Current and future therapeutic approaches to hyperlipidemia[J]. Adv Pharmacol, 1996,35:79 - 114.
  • 6秦晋梅,李建军.他汀类药物的抗炎作用[J].中国动脉硬化杂志,2004,12(3):363-366. 被引量:42
  • 7覃军,李爱民,何作云.他汀类药物对血管平滑肌细胞的直接作用及其意义[J].中国动脉硬化杂志,2000,8(4):373-375. 被引量:17
  • 8Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of humanhypertrophic cardiomyopathy [ J ]. Circulation,2001,104 ( 3 ) :317 - 24.
  • 9Borghi C, Prandin MG, Costa FV, et al. Use of statins and blood poressure control in hypertensive patients with hypercholesterolemia [ J ]. J Cardiovasc Pharmacol,2000,35 (4) :549 - 55.
  • 10Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats [ J ]. Hypertension, 1997,30 (4) : 968 - 74.

二级参考文献46

  • 1Simes J, Furberg CD, Braunwald E, Davis BR, Ford I, Tonkin A, et al.Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels.The Prospective Pravastatin Pooling project.Eur Heart J, 2002, 23 (3):207-215
  • 2Scandinavian Simvastatin Survival Study Group.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study (4S).Lancet, 1994, 344:1 383-389
  • 3Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels:results of AFCAPS/TexCAPS.Air Force/Texas Coronary Atherosclerosis Prevention Study.J Am Med Assoc, 1998, 279 (20):1 615-622
  • 4Plutzky J, Ridker PM.Statins for Stroke:The Second Story? Circulation, 2002, 103 (3):348-350
  • 5Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al.Effect of pravastatin on outcomes after cardiac transplantation.N Engl J Med, 1995, 333 (10):621-627
  • 6Wenke K, Meiser B, Thiery J, Nagel D, Scheidt WV, Steinbeck G, et al.Simvastatin reduces graft vessel disease and mortality after heart transplantation.Circulation, 1997, 96 (5):1 398-402
  • 7Strandberg TE, Vanhanen H, Tikkanen MJ.Effect of statins on C-reactive protein with coronary artery disease.Lancet, 1999, 353(9147):118-119
  • 8Rider PM, Rifai N, Pfeffer M, Sacks F, Braunwald E.For the cholesterol and recurrent event (CARE) investigators.Long-term effects of pravastatin on plasma concentration of C-reactive protein.Circulation, 1999, 100 (3):230-235
  • 9Albert MA, Staggers J, Chew P, Rider PM.The pravastatin inflammation CRP evaluation (PRINCE):rationale and design.Am Heart J, 2001, 141 (6):893-898
  • 10Albert MA, Danielson E, Rifai N, Ridker PM.Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation / CRP Evaluation (PRINCE):A randomize trial and cohort study.J Am Med Assoc, 2001, 286 (1):64-70

共引文献67

同被引文献58

  • 1高培平,田德峰,司书毅.调血脂药物的研究进展[J].中国药学杂志,2005,40(24):1849-1852. 被引量:2
  • 2薛红,张晔,王旭开,杨成明,王红勇,傅春江.阿托伐他汀与硝苯地平控释片的协同降压作用及对血管内皮功能的影响[J].第三军医大学学报,2006,28(15):1616-1618. 被引量:5
  • 3吴桥.辛伐他汀治疗不稳定心绞痛40例疗效观察[J].安徽医药,2007,11(1):21-22. 被引量:16
  • 4李洪林,杨思进.他汀类药物调脂作用外的临床研究进展[J].中国药房,2007,18(17):1352-1354. 被引量:8
  • 5Rauch U,Osende JI,Chesebro JH.Statins and cardiovascular diseases:the mutiple effects lipid-lowing therapy by statins[J].Atherosclerosis,2000,153(1):181-9.
  • 6Frolkis JP,Pearce GL,Nambi V.Statins do not meet expectatings for lowering low-density lipoprotein cholesterol levels when used in clinical practice[J].AM J Med,2002,113(8):625-9.
  • 7中华医学心血管病分会.关于高血压患者及早启动降压联合他汀的建议[N].中国医学论坛报,2011-9-8(A12).
  • 8Jantzen F, Nemann S, Wolff B, et al. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and incereases NO synthase activity in human um- bilical vein endothelial cells [ J ]. Journal of Physiol and Pharmacol, 2007,58 ( 3 ) :503 - 514.
  • 9Tycinska AM, Janica J, Mroczko B, et al. I-Iypotensive effect of atorv- astatin in hypertensive patients:the association among flow-m func- tion[J]. Arch Med Sci,2011,7(6) :955 -962.
  • 10Kuklinska AM, Mroczko B, Musial WJ, et al. Influence of atorvasta- tin on blood pressure control in treated hypertensive, normolipemic patients - An open, pilot study [ J ]. Blood Press, 2010,19 ( 4 ) : 260 - 266.

引证文献5

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部